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1. Introduction 
Substance abuse is a continuing problem in the United States (US), impacting the individual 
and their social networks, and impacting society, economically and through public health 
programs. According to the 2004 National Household Survey on Drug Abuse (NHSDA), 
there were 19.1 million illicit drug users in the US. Drug use is directly and indirectly related 
to three blood-borne diseases, HIV, HBV and HCV. Direct exposure occurs through needle 
sharing and sharing other paraphernalia used to prepare and inject drugs [1-5]. The 
probability of direct exposure to HIV varies in relation to the procurement, preparation, and 
injection practices of drug users [6-10]. Frequency of injection and duration of injection are 
major factors for acquisition of HBV or HCV infections [11-13]. IDU is the primary mode of 
transmission of HCV in the US [14].  
Drug use indirectly contributes to HIV exposure by decreasing inhibitions to engage in 
high-risk sexual activities and/or increased inhibitory effects on achieving sexual 
satisfaction [8, 15]. The use of cocaine has been shown to affect biological and behavioral 
processes related to HIV infection [16-19]. Engaging in risky sexual behaviors associated 
with drug use remains a significant risk factor for the acquisition of HBV, also, by men 
having sex with men (MSM) or heterosexual transmission. This interrelationship between 
drug use and high-risk sexual behavior makes it crucial to understanding the drug user 
population in order to develop appropriate interventions [20].  
Houston is the fourth largest city and has the eighth highest AIDS caseload in the US. The 
number of African American and Hispanic Houstonians diagnosed with AIDS are 
increasing. The reason for the change in focus of the epidemic in Houston, from MSM to 
persons of color, may be related to the use of crack cocaine [4, 5]. Smoking crack cocaine, 
which became widespread in many poor, African American neighborhoods in the mid-
1980s, continues to dominate the inner city drug use scene, and crack smokers, in addition to 
www.intechopen.com
 
Insight and Control of Infectious Disease in Global Scenario 
 
46
injection drug users, are at elevated risk for HIV infection. HBV and HCV were endemic 
among injecting drug users, even before HIV was introduced into this population. Common 
risk factors for these blood-borne viral agents, such as multi-person use of injecting 
equipment and sexual behaviors, have resulted in a high prevalence of infection of all three 
viruses among drug users. However, a significant proportion does remain at risk, as our 
previous studies in Houston have shown [4, 5] and should be targeted for vaccine 
prevention. 
The purpose of this study was to estimate the prevalence of HIV, HBV and HCV infections 
and associated socio-demographic, drug use and sexual risk factors in a sample of 
predominantly African American injecting and non-injecting drug users who were recruited 
for a HBV vaccination study in Houston, Texas.     
2. Material and methods 
2.1 Study population 
A sample of 2,779 injecting and non-injecting drug users was recruited for a community-
based HBV vaccine study from February 2004 to October 2007. Participants were recruited 
from targeted congregation sites such as copping areas, street corners, and crack houses 
from predominantly two inner city neighborhood communities of Houston, Texas, by using 
outreach and chain referral recruiting methods. Target neighborhoods were selected based 
on previous studies [4, 5]. Potential study participants were asked to go to the designated 
field site in the area where they were recruited. The eligibility criteria for the study were 1) 
ages 18 and over, 2) local residence, 3) self-report and confirmed urine drug screen, 4) 
competent and willing to sign an informed consent form for HIV, HBV, and HCV antibody 
testing. This study had Institutional Review Board (IRB) approval through the University of 
Texas Health Science Center Committee for the Protection of Human Subjects.  
2.1 Data collection 
Data collectors received extensive training in obtaining informed consent, keeping 
participant information confidential, and administering the questionnaire. The interview 
was conducted confidentially in a private office and was identified only by a unique study 
identification number. Socio-demographic measures such as age, gender, race/ethnicity, 
living arrangement, jail history of >24 hours; drug use history including lifetime injection 
drug use (IDU), times injected drugs in past 7 and 30 days, lifetime and number of times 
shared needles in past 30 days, duration of IDU, types and frequency of drugs used in past 
48 hours, 7 and 30 days, and drug treatment history; sexual behaviors such as number of 
sexual partners in the past 30 days, sexual orientation, condom use, history of sexually 
transmitted diseases, and trading sex for money or drugs in the past 30 days; history of 
blood transfusion and occupational exposure to blood. All interviews were verbally 
administered and recorded electronically via computer administered personal interview 
(CAPI, QDS, Bethesda, Maryland).    
After the interview was completed, drug use was confirmed via urine drug screen, using 
OnTrak TesTstik, (Varian Inc,. Palo Alto, CA) to test for the presence of cocaine, opiates, 
and/or methamphetamines. Participants with a positive drug screen were asked to provide 
10 ml of peripheral venous blood. Participants received a gratuity of $10.  
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2.2 Laboratory methods 
Specimens were screened for HIV 1/2 antibodies, hepatitis B surface antigen (HBsAg), and 
antibodies to HCV (anti-HCV) by Core Combo HIV-HBsAg-HCV (Core Diagnostics, United 
Kingdom). Verification of HIV occurred by enzyme immunoassay (EIA), anti-HIV, using 
Abbott PPC Commander system, third generation HIV antibody test (Abbott Laboratories, 
Chicago, IL) , to HCV  (Anti-HCV), hepatitis B surface antigen (anti-HBs) and antibody to 
hepatitis B core antigen (anti-HBc), by the Abbott AxSYM system, using microparticle 
enzyme immunoassay (MEIA) (Abbott Laboratories, Chicago, IL).  
Case definition for HIV infection was repeatedly reactive specimen by EIA. The detection of 
HBsAg or anti-HBc, with or without anti-HBs was the definition of HBV infection. HCV 
infection definition was based on the presence of antibody to HCV. We have 2,779 
observations for the HIV analysis, 1,712 for HBV analysis and 1,867 for HCV analysis at the 
time of manuscript preparation.  
2.3 Statistics 
Data from the questionnaire was imported into SAS 9.1 (Cary, NC) and laboratory results 
were entered into a Microsoft Access database. Data analysis was performed using STATA 
9.0 (College Station, TX) software. Prevalence of HIV, HBV and HCV infections were 
estimated for the overall population and stratified by injecting status. Univariate and 
multivariable logistic analyses were performed. Any variable demonstrating a p-value of 0.2 
or less or was biologically plausible was carried forward from univariate to multivariable 
analyses. Variables in the multivariable analyses that had a p-value of 0.05 or less were 
retained as the final model. Asian and other race were combined with Hispanic race because 
of small numbers. Variables with more than 10% missing responses from participants were 
not considered reliable enough to be examined. 
3. Results  
3.1 Demographic characteristics of the participants 
Out of the 2,779, 85% of participants were African American, 11% White, and 4% Hispanic 
or other race with the majority (76%) being male. The median age was 43 and ranged from 
18 to 76 years. About 3% reported having received a transfusion and the majority (78%) had 
a history of being in jail > 24 hours. Twelve percent were currently living in a shelter, and 
62% had a history of being in a drug treatment program.  
Almost 98% of the study participants had smoked crack in the past 7 days, 5% used 
methamphetamines and 5% were heroin users. About one-third (32%) had a history of 
injection drug use and 13% had a history of sharing needles. Almost half (43%) reported less 
than 50% condom use in the past 30 days. Nearly two-thirds (68%) reported a history of 
STD, with syphilis (42%) and gonorrhea (50%) being the two most prevalent. About one-
fifth (19%) of the study population included MSM, more than one-third had traded sex for 
money/drugs in the past 30 days, and 23% reported having  >3 male sexual partners and 
40% had >3 female sexual partners in past 30 days. 
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3.2 Prevalence and risk factors associated with HIV infection 
The prevalence of HIV infection in this population was 8.7%. Variables that had a significant 
association with being HIV infected in the univariate analysis were gender, shelter status, 
sexual orientation, condom use, MSM, trading sex for money or drugs in the past 30 days, 
and number of sex partners in the past 30 days (Tables 1 and 2). The drug-related variables 
explored in this analysis did not demonstrate any significant associations. After adjustment, 
HIV positive participants were more likely to be African American {OR= 2.8 (95% CI 1.6, 
4.9)}, Hispanic and other race {OR= 2.5 (95% CI 1.1, 5.7)}, men having sex with men {OR= 2.5 
(95% CI 1.7, 3.5)}, consistent condom users {OR= 2.9 (95% CI 2.0, 4.2)}, and be a male or 
female that had more than three male partners in the past 30 days {OR= 1.6 (95% CI 1.0, 2.4)} 
(Table 3). Study participants that lived in a shelter {OR= 0.5 (95% CI 0.3, 0.9)} or a male or 
female participant that had more than three female partners in the past 30 days {OR= 0.4 
(95% CI 0.2, 0.5)} were less likely to be HIV positive (Table 3).  
 
 
 
Variables 
Total 
Number (%)
HIV 
Positive (%) 
HBV 
Positive (%) 
HCV 
Positive (%) 
Total 2779 (100%) 8.7% 44.8% 36.1% 
Gender     
Male 2111 (76%) 7.8%* 43.7% ∆ 37.5%* 
Female 668 (24%) 11.7% 48.8% 30.8% 
Age (years)     
≤29 341 (12%) 7.7% 22.5%* 10.3%* 
30-39 682 (25%) 10.7% 34.4% 20.7% 
40-49 1177 (42%) 9.1% 50.1% 44.2% 
>=50 579 (21%) 6.4% 57.5% 54.6% 
Race/ethnicity     
Caucasian 302 (11%) 6.0% 37.9%* 53.4%* 
Blacks 2354 (85%) 9.0% 46.3% 32.9% 
Others 123 (4%) 10.6% 32.9% 55.7% 
Currently living in a shelter     
No 2458 (88%) 9.2%* 45.0% 35.6% 
Yes 321 (12%) 4.7% 43.3% 39.5% 
Ever in drug treatment     
No 1070 (38%) 9.3% 43.3% 30.1%* 
Yes 1709 (62%) 8.3% 45.7% 39.7% 
Ever received a transfusion     
No 2692 (97%) 8.7% 43.8%* 34.1* 
Yes 87 (3%) 8.0% 53.1% 54.0 
Ever in Jail >24 hours     
No 613 (22%) 9.5% 41.3% 27.5%* 
Yes 2166 (78%) 8.5% 45.6% 38.3% 
*P value <0.05 
 
Table 1. Prevalence of HIV, HBV and HCV infections among demographic characteristics in 
drug users, Houston, Texas. 
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Variables Total 
HIV 
positive 
N(%) 
HBV 
positive 
N(%) 
HCV 
positive 
N(%) 
Drugs use in past 7 days     
No 16 (1%) 0% 46.2% 23.1% 
Yes 2763 (99%) 8.8% 45.0% 36.2% 
Marijuana     
No 1289 (46%) 8.5% 45.8% 38.3% 
Yes 1490 (54%) 8.9% 43.8% 34.2% 
Methamphetamines     
No 2632 (95%) 8.9% 45.1% 35.5%* 
Yes 147 (5%) 6.1% 39.0% 47.2% 
Cocaine     
No 62 (2%) 11.3% 48.0% 48.2% 
Yes 2717 (98%) 8.6% 44.7% 36.0% 
Heroin     
No 2636 (95%) 8.8% 43.9%* 34.8%* 
Yes 143 (5%) 7.0% 59.8% 61.6% 
Ever injected drugs     
No 1829 (66%) 8.6% 36.6%* 17.9%* 
Yes 950 (34%) 8.8% 59.6% 70.0% 
Duration of Injecting     
<5 years 2218 (80%) 8.5% 36.0%* 26.5%* 
>5 years 561 (20%) 9.4% 63.9% 78.3% 
Ever shared needle/work     
No 2407 (87%) 8.7% 43.0%* 30.2%* 
Yes 369 (13%) 8.4% 55.1% 72.1% 
History of STD     
No 875 (32%) 7.9% 37.0%* 30.1%* 
Yes 1904 (68%) 9.1% 48.9% 39.3% 
History of Syphilis     
No 1597(58%) 8.5% 41.4% 34.5%* 
Yes 1182(42%) 9.1% 51.1% 39.3% 
What % of use a condom:     
Never 1095 (41%) 5.7%* 40.9% 35.5% 
Sometimes 1137 (43%) 9.2% 40.5% 36.5% 
Always 445 (16%) 14.2% 40.3% 33.1% 
Sexuality     
Homosexual 112 (4%) 32.1%* 50.0% 32.0%* 
Heterosexual 2137 (77%) 7.1% 44.7% 34.7% 
Bisexual 530 (19%) 10.2% 44.2% 42.1% 
Men had sex with men     
No 2248 (81%) 7.3%* 45.4% 36.1% 
Yes 531 (19%) 14.7% 44.7% 36.2% 
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Variables Total 
HIV 
positive 
N(%) 
HBV 
positive 
N(%) 
HCV 
positive 
N(%) 
Traded sex for money/drugs past 30 
days 
    
No 1832 (66%) 7.3%* 45.1% 36.1% 
Yes 947 (34%) 11.4% 44.0% 36.2% 
Number of male sex partners in the 
past 30 days 
    
0 1732 (63%) 6.0%* 43.9% 37.3% 
1-2 401 (14%) 10.2% 45.9% 33.2% 
>=3 630 (23%) 15.2% 47.4% 34.4% 
Number of female sex partners in 
the past 30 days 
    
0 919 (33%) 14.0%* 50.0%* 37.0% 
1-2 759 (27%) 6.9% 41.6% 37.7% 
>=3 1091 (40%) 5.5% 43.5% 33.9% 
*P value <0.05  
Table 2. Prevalence of HIV, HBV and HCV Infections by Drug Use and Sexual Behavior 
Variables in Past 30 Days among Drug Users in DASH Project. 
 
 HIV HBV HCV 
Risk Factors OR (95% CI) OR (95% CI) OR (95% CI) 
Race/Ethnicity    
White 1.00   
African American 2.8 (1.6-4.9)  * 1.7 (1.2-2.4)* 0.4(0.3-0.6)* 
Other 2.5 (1.1-5.7)  * 0.9(0.5-1.6) 1.5(0.8-2.8)* 
Age (per year) 1.00 (0.98-1.02) 1.05 (1.04-1.06)* 1.10(1.08-1.12)* 
Injecting Drug use    
Yes 1.11 (0.8-1.5) 2.7 (2.27-3.5)* 9.4 (7.4-12.1)* 
Shelter    
Yes 0.5(0.3-0.9)* ----- ------ 
History of blood 
transfusions 
   
Yes ------ ------ 1.6 (1.1-2.3)* 
Condom use    
Always 2.9 (2.0-4.2) * ------ ------ 
Sometimes 1.5(1.1-2.2)*   
History of syphilis 
diagnosis 
   
Yes ------ 1.30(1.05-1.61)* ------ 
Men had sex with men    
Yes 2.5 (1.7-3.5) * ------ ------ 
No. of male sex partners 
last 30 days 
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 HIV HBV HCV 
Risk Factors OR (95% CI) OR (95% CI) OR (95% CI) 
>3 1.6 (1.0-2.4)* ------ ------ 
No. of female sex 
partners last 30 days 
   
>3 0.4(0.2-0.5)* 0.6(0.5-0.8)* ------ 
1-2 0.5(0.4-0.8)*   
*P value <0.05 
Table 3. Multivariable Analyses of Risk Factors for HIV, HBV, HCV Infections Among Drug 
Users, Houston, TX. 
To determine if associations differed between females and males and IDUs and non-IDUs, 
stratification by gender and injecting status were explored. The male study population 
analysis did not differ from the results from the total study population above (data not 
shown). Among the 668 female participants, African American race {OR 3.64 (95% CI 1.07-
12.36)} and always using condoms in the past 30 days {OR 2.18, (95% CI, 1.10-4.33)} were 
found to be independently associated with HIV infection. Among non-injectors and 
injectors, the results from the multivariable analyses were fairly consistent with what was 
found in the total study population (Table 5).  
Stratification also occurred by MSM status (Table 5) to determine if MSM status masked 
IDU as a risk factor for HIV. IDU status was not a significant risk factor for HIV in either the 
non-MSM or MSM analyses (Table 5).       
3.3 Prevalence and risk factors associated with Hepatitis B virus infection 
The prevalence of HBV in this study was 44.8%. Seropositivity for HBsAg (carrier) was 2.0% 
and for anti-HBc (previous or current infection), 38.5%. Of those with HBV infection, 412 
(53.7%) out of 766 were co-infected with HCV. In Table 1 and 2, significant differences were 
observed between HBV positive and negative participants in variables representing gender, 
age, race, transfusion history, use of heroin in the past 30 days, number of sex partners in the 
past 30 days, history of STD, history of injection drug use, and history of sharing needles or 
works. After adjustment in the multivariable analysis, African American race {OR= 1.7 (95% 
CI 1.2, 2.4)}, increasing age per year {OR= 1.05 (95% CI 1.04, 1.06)}, history of injection drug 
use {OR= 2.7 (95% CI 2.3, 3.5)}, and having a history of being  diagnosed with syphilis {OR= 
1.3 (95% CI 1.05, 1.61)} remained independently associated with HBV infection, while 
having more than 3 female partners in 30 days, whether male or female, was inversely 
related to HBV infection {OR= 0.6 (95% CI 0.5, 0.8)} (Table 3). 
To determine if non-IDUs shared the same risk characteristics as IDUs for HBV infection, 
stratification by injection status occurred. After adjusting for confounders in the 
multivariable analysis, two risk factors for HBV infection remained significant among non-
injectors, increasing age and history of STD, while females or males with more than three 
female partners were less likely to have HBV infection (Table 4). Injectors that had 
increasing age, of African American race, female and had injected drugs for more than 5 
years were all at risk for HBV infection after adjustment (Table 4).  
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 HBV HCV 
Risk Factors 
NIDU 
OR 
(95%CI) 
IDU 
OR 
(95%CI) 
NIDU 
OR 
(95%CI) 
IDU 
OR 
(95%CI) 
Gender     
Male 1.0(0.7-1.4) 1.8(1.1-2.9)* 0.9(0.6-1.3) 1.5(0.9-2.5) 
Race/Ethnicity     
White     
African 
American 
1.1(0.6-2.1) 1.7(1.1-2.9)* 0.5(0.2-097)* 0.4(0.2-0.7)* 
Others 0.4(0.1-1.4) 1.0(0.5-2.2) 1.5(0.5-4.5) 1.3(0.5-3.0) 
Age (per year) 1.03(1.01-1.04)* 1.09(1.07-1.12)* 1.09(1.07-1.12)* 1.10(1.07-1.13)* 
Transfusion 
History 
    
Yes ----- ----- 1.8(1.1-2.93) ----- 
History in jail 
>24 hours 
    
Yes ----- ----- 2.5 (1.5-4.1)* ----- 
Duration of IDU     
>6 years ----- 2.1(1.4-3.1)* 2.0(1.4-3.0)* ----- 
Men sex with 
men 
    
Yes -----  ----- ----- 
History of STDs     
Yes 1.5(1.1-1.9)*  ----- ----- 
Number male 
sex partners 
    
>3 partners -----  ----- ----- 
Number female 
sex partners 
    
>3 partners 0.6(0.4-0.9)*  ----- ----- 
*P value <0.05 
 
 
 
 
Table 4. Multivariable Analyses of Risk Factors for HIV Infection Stratified by Injecting 
Status Among Drug Users, Houston, Texas. 
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 HIV HIV 
Risk Factors 
NIDU 
OR 
(95%CI) 
IDU 
OR 
(95%CI) 
Not MSM 
OR 
(95%CI) 
MSM 
OR 
(95%CI) 
Gender     
Male   0.52(0.07-3.84) ----- 
Race/Ethnicity     
White 1.00  1.00 1.00 
African 
American 
1.9(0.8-4.4) 2.5(1.1-5.5)* 4.93(1.53-15.87)* 2.27(1.04-4.93)* 
Others 1.2(0.3-5.0) 3.1(1.2-8.3)* 5.97(1.42-25.07)* 1.71(0.54-5.35) 
Age (per year) 1.0(0.98-1.02) 1.0(0.97-1.03) 1.00(0.98-1.02) 1.01(0.98-1.04) 
Shelter     
Yes 0.3(0.1-0.9)*  ----- 0.39 (0.15-1.00)* 
Ever IDU     
Yes -----  ----- 0.61(0.34-1.10) 
Men sex with 
men 
    
Yes 2.5(1.6-3.9)* 1.8(1.0-3.3)* ----- ----- 
History of 
Chlamydia 
    
Yes -----  ----- 0.11(0.03-0.38)* 
History of genital 
warts 
    
Yes -----  ----- 3.28(1.00-10.77)* 
Condom     
Never   1.00 1.00 
Always 2.1(1.3-3.4)* 5.6(2.8-11.4)* 2.85 (1.81-4.48)* 3.51(1.56-7.88)* 
Sometimes  2.7(1.4-5.1)* 1.45(0.95-2.21)* 2.14(1.12-4.09)* 
Number male 
sex partners 
    
0   1.00  
1-3 partners   4.38(0.58-33.32)  
>3 partners 2.6(1.5-4.5)*  6.92(0.92-52.12)  
Number female 
sex partners 
    
0    1.00 
1-3 partners    0.26(0.13-0.53)* 
>3 partners 0.4(0.3-0.7)* 0.4(0.2-0.7)*  0.16(0.08-0.31)* 
IDU stratification adjusted for history in jail for >24 hours, duration of IDU, history of STDs  
MSM stratification adjusted for alcohol use, methamphetamine, cocaine use in the past 30 days, crack 
use in the past 48 hours, duration of IDU, trading for sex/money past 30 days, history of syphilis or 
genital herpes   
*p value<0.05 
Table 5. Multivariable Analyses of Risk Factors for HIV Infection Stratified by Injecting 
Status and MSM Status Among Drug Users, Houston, Texas. 
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3.4 Prevalence and risk factors associated with Hepatitis C virus infection  
The prevalence of HCV infection in this population was 36.1%. Of 668 participants infected 
with HCV, 61.7% were coinfected with HBV. In Tables 1 and 2, gender, age, race, history of 
drug treatment, history of transfusion, history of being in jail for >24 hours, sexuality, 
methamphetamine use, heroin use, history of injecting drugs, history of sharing needles or 
works, sexuality, history of STD, and history of diagnosis or treatment for syphilis all 
showed significant differences between HCV positive and negative participants 
univariately. After adjustment in the multivariable analysis,  increasing age {OR= 1.10 (95% 
CI 1.08, 1.12)}, history of injection drug use {OR= 9.4 (95% CI 7.4, 12.1)}, and having a history 
of a transfusion {OR= 1.6 (95% CI 1.1, 2.3)}were all still independently associated with HCV 
infection, while African American race was inversely related to HCV infection {OR= 0.4 
(95% CI 0.3, 0.6)} (Table 3). 
Because of the striking difference between injectors (70%) and non-injectors (17.9%) in HCV 
positive study participants, and the overwhelming magnitude of association between 
injection drug use status and HCV positivity, stratification by injection status was 
performed to uncover risk characteristics of non-IDUs that may have been masked. In the 
multivariable analysis, increasing age and having a history of transfusion were found to be 
independently associated with HCV infection among non-IDUs. African American race was 
inversely related with HCV infection (Table 4). The significant variables associated with 
HCV infection among injectors after adjustment were increasing age, having been in jail for 
more than 24 hours, and injecting drugs for more than 5 years, while African American race 
remained inversely associated with HCV infection (Table 4).  
4. Discussion 
This is the first study to evaluate both IDUs and non-IDUs for HIV, HBV and HCV 
infections in not-in-treatment urban community settings. In this study, prevalence of HIV, 
HBV, and HCV was 9%, 45% and 36% respectively. The predominant risk characteristics 
associated with HIV infection in drug users are sexual behaviors, especially MSM, while the 
predominant risk characteristic associated with HBV and HCV infections is injection drug 
use. African American race among IDUs is positively associated with HIV and HBV 
infections and inversely associated with HCV infection. Increasing age is significantly 
associated with HBV and HCV infections, but not with HIV infection. Duration of injection 
drug use is also significantly associated with HBV and HCV infections.  
Sexual behaviors are the most prevalent risk factors associated with HIV in this study of 
primarily African American crack cocaine users, which we have found in our previous 
studies [4, 5]. Any altering substance, such as crack cocaine and methamphetamines, can 
influence a person to engage in higher frequencies of risky sexual acts, which increases the 
total number of exposure events, resulting in a higher likelihood of being infected with HIV 
[17, 21-23]. Crack cocaine is the drug of choice in this study, as 98% of the participants used 
this drug, with very few using other drugs, such as methamphetamines. Several studies 
have shown that crack cocaine users engage in more unprotected sexual acts, trade sex for 
money or drugs and have more sexually transmitted diseases, all factors contributing to 
greater risk for HIV infection [17, 21, 23-26]. One third of the study participants had a 
history of injection drug use, but no associations were identified between IDU and HIV 
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infection in males or females in this study, a conflicting finding from other studies [27-31]. 
Therefore, crack cocaine use and resulting sexual behaviors from its use infer the most likely 
way HIV is transmitted amongst drug users in this population.  
Study participants that had more than 3 male partners were more likely to have HIV than 
study participants with less male partners in the past 30 days, emphasizing the point of 
higher frequencies of sexual acts increases exposure. This result remains significant for non-
IDU HIV infected study participants and non-MSM female study participants. Non-IDU and 
IDU HIV infected MSMs show greater likelihood of infection, adding credence to this 
finding. Two variables to help explain these risky sexual acts, condom use and trading sex 
for money or drugs, failed to show a significant association in this study, after adjustment 
for other variables. Men traded sex for money or drugs more often than women in this 
study, but neither group showed a significant association. However, 40% of the men that 
traded sex had at least one male sexual partner in their lifetime, clouding the association 
between HIV infection and trading sex due to the collinearity of “trading sex” and “MSM” 
variables. Frequency of partners may have also been collinear with trading sex, and they 
really point to the same issue, whether being male or female, heterosexual or homosexual, 
the more partners and unprotected acts one has, the increase in likelihood for exposure to 
HIV. Of note, the measurement tool captured sexual activity in the past 30 days, not lifetime 
risk, and prevalent data does not necessarily reflect the risk profile of the study participant 
at the time of HIV acquisition. This is the case with condom use. Study participants were 
more likely to be HIV infected and always use a condom.  
The majority of study participants in this study are African American. It is important to note 
that studies on African American male sexual behaviors show incongruity between reported 
sexual identity and actual behavior, greater in African American MSM, but other races as 
well [32]. Williams et al. [33] conducted qualitative analyses of HIV positive gay identifying 
and non-gay identifying African Americans, and revealed consequences of alienation, low 
self-esteem, unsupportive networks, a need to protect their HIV status, and inconsistent 
condom use after acknowledgement of the importance of condom use due to race and 
sexual orientation status. The higher prevalence of HIV in African American MSM and their 
higher level of bisexual activity can put African American women at risk, therefore 
identifying two high risk groups where sensitive interventions need to be developed and 
delivered in supportive surroundings. Our study also alludes to the importance of African 
American MSM and their risk for HIV infection. In the MSM stratification analysis, minority 
races were significantly more at risk for HIV infection versus Caucasians. Most of our MSM 
were African American, 69%, followed by Caucasian, 24%, further heightening the urgency 
to reach this very high risk group. In this group of drug users, having a male partner, 
whether bisexual or homosexual, is an overwhelming risk factor for HIV infection, and may 
be interrelated with injection drug use. IDU does not show to be a significant risk factor in 
this study for HIV infection, however, the correlation between MSM status and IDU status 
may be masking the true association. It is logical to assume that an MSM-IDU has the 
greatest risk for HIV infection.       
While sexual practices were associated with HIV infection, injecting practices were 
significant factors associated with HBV or HCV infection in this same population. This 
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study supports previous work that risky injection drug use practices result in the 
transmission of HBV or HCV [4, 7, 11, 13, 34-36], and the longer one injects, in regards to age 
and duration, in a high risk population, the more likely the person will be infected [11-13, 
37, 38]. However, sharing needles was not associated with HBV or HCV in this study, 
contrasting a previous study by our principal investigator [4], and others [13]. This most 
likely reflects the strong correlation between history of injection drug use and sharing 
paraphernalia occurring in this study.  
African American IDUs in this study were less likely to have HCV infection, but were more 
likely to have HBV infection, a conclusion supported by two other studies that did not 
stratify by injection drug use [4, 39]. One last finding associated with HCV infection among 
IDUs is history of being in jail for at least 24 hours or more. Possible explanations that were 
not explored in this study but were found in other studies are sharing needles in jail, and/or 
receiving a tattoo in jail, but all consistently found a high prevalence of HCV in the 
prison/jail systems, heightening the risk for HCV infection [13, 40, 41].      
Non-injecting drug users with HBV infection were more likely to have reported a history of 
STD and be older, but less likely to have more than 3 female sex partners. Non-injectors with 
HCV infection were associated with transfusion history, increasing age, but less likely to be 
African American. The median age of the study participants in this study is 43, and 
documented to be participating in risky drug and sexual behaviors, plus vulnerable to 
infection, therefore, increasing age is an understandable risk. Sexual behavior in non-
injecting drug users may be influenced by stimulant drug activity, especially crack cocaine 
[17, 21, 23-26], influencing the drug user to participate in risky sexual behaviors, resulting in 
increased risk for HIV, hepatitis B, and STDs. From our previous studies and others, there 
was no significant association found between HCV infection and sexual risk behaviors [4, 
34]. Transfusion-associated HCV has been documented [42].           
HIV, HBV, and HCV infections, drug use behaviors, and social network dynamics vary 
widely between populations, even at the neighborhood level. This analysis applies directly 
only to drug users in the urban neighborhoods in Houston, although generalizations about 
urban drug users may be used to guide further research in other communities. Every 
attempt to limit recall bias by limiting the reference period for recall of events and reporting 
bias through using discretion in interviewing and questions deemed appropriate 
throughout the pilot study was made, but some bias inevitably exists in the data. High-risk 
activity may have changed with time, either independent of or dependent on, one’s HIV or 
HBV/HCV serostatus, masking true associations that were not covered by the timeframe in 
question or creating the appearance of spurious associations between HIV or HBV/HCV 
and current behaviors that had not been expressed at the time of infection.  
Characterizing determinants of risk for HIV, HBV, or HCV infection among drug users will 
improve targeting of health services and prevention education. The greatest association 
between HIV and drug users in this study was sexual practices, while injecting drug use 
was the greatest factor associated with HBV and HCV infections. African American drug 
users are disproportionately affected by these three blood-borne diseases. The vaccine for 
HBV is being underutilized in high risk drug users, and outreach efforts to understand the 
barriers to accepting HBV vaccination need to be explored to prevent further HBV 
transmission. Studies targeting young drug users to prevent initiation into injecting or curb 
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injecting soon after initiation combined with using social networks for counseling about 
prevention of these three diseases will impact and interrupt transmission cycles.        
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